Treatment with rituximab, a monoclonal antibody against CD20, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has been used in patients with diffuse large B-cell lymphoma (DLBCL) for more than 15 years with proven efficacy and safety \[[@CR1]\]. With demonstrated highly similar analytical characterization and bioequivalence in pharmacokinetics and pharmacodynamics \[[@CR2]\], we conducted this phase 3, multi-center, randomized, parallel, double-blind study (HLX01-NHL03) to establish the equivalence in clinical efficacy, safety, and immunogenicity between HLX01 plus CHOP (H-CHOP) and R-CHOP every 21 days for up to six cycles in treatment-naïve patients with CD20-positive DLBCL.

Eligible patients were treatment-naïve adults (≥ 18 to ≤ 80 years) with International Prognostic Index of 0-2, clinical stages I--IV (Ann Arbor Staging) and histologically confirmed CD20-positive DLBCL. The primary efficacy endpoint was best overall response rate (ORR) within six cycles of treatment in the per-protocol set (PPS), and secondary efficacy endpoints included complete response rate, 1-year duration of response, 1-year event-free survival, 1-year progression-free survival, 1-year disease-free survival, 1-year overall survival, and depletion of CD19-positive B-cells in peripheral blood.

From October 9, 2015 to March 10, 2017, a total of 560 patients were screened, of whom 407 patients were randomized (1:1) at 33 investigational sites; 361 patients (H-CHOP 173; R-CHOP 188) completed six cycles of treatment, and 328 patients (H-CHOP 157; R-CHOP 171) completed the study (Fig. [1](#Fig1){ref-type="fig"}a). Baseline characteristics are well balanced between two treatment groups (Fig. [1](#Fig1){ref-type="fig"}b). In the PPS, the best ORRs within six cycles of treatment in the PPS were 94·1% (95% confidence interval \[CI\], 89.77 to 97.04) and 92·8% (95% CI, 88.19 to 96.00) in the H-CHOP and R-CHOP groups, respectively, with an intergroup difference of 1.4% (95% CI, − 3.59 to 6.32, *p* = 0.608). The efficacy equivalence between HLX01 and reference rituximab was demonstrated with 95% CIs falls entirely within the pre-defined margin of ± 12%. The results of using the full analysis set (FAS) were consistent with the primary efficacy analysis in the PPS. Previous reports of R-CHOP in patients with DLBCL have shown ORRs ranging between 83% and 88% \[[@CR3], [@CR4]\], which is comparable with the result from this study. No significant differences were observed in the 1-year analysis of all secondary efficacy endpoints, in either the PPS or the FAS (Table [1](#Tab1){ref-type="table"}). Fig. 1**a** Patient disposition of all screened patients. **b** Baseline patient demographics and disease status of full analysis dataset (FAS)Table 1Efficacy outcomesPer-protocol datasetFull analysis datasetH-CHOP (***n*** = 188)R-CHOP (***n*** = 194)***P*** valueH-CHOP (***n*** = 199)R-CHOP (***n*** = 203)***P*** valueBest overall response rate177 (94·1)180 (92·8)0·608184 (92·5)187 (92·1)0·839 Complete response88 (46·8)101 (52·1)0·23190 (45·2)104 (51·2)0·190 Partial response89 (47·3)79 (40·7)94 (47·2)83 (40·9) Stable disease8 (4·3)13 (6·7)11 (5·5)15 (7·4) Disease progression2 (1·1)1 (0·5)2 (1·0)1 (0·5) No evidence of disease1 (0·5)02 (1·0)0Duration of response Patients experiencing events25 (13·8)21 (11·5)0·42426 (13·7)21 (11·1)0·355 Patients censored156 (86·2)161 (88·5)164 (86·3)168 (88·9)Event-free survival Patients experiencing events80 (42·6)67 (34·5)0·12588 (44·2)71 (35·0)0·087 Patients censored108 (57·4)127 (65·5)111 (55·8)132 (65·0) 1-year event-free survival rate55·4 (47·9, 63·0)64·5 (57·6, 71·4)53·7 (46·4, 61·0)63·4 (56·6, 70·2)Progression-free survival Patients experiencing events31 (16·5)29 (14·9)0·53433 (16·6)30 (14·8)0·473 Patients censored157 (83·5)165 (85·1)166 (83·4)173 (85·2) 1-year progression-free survival rate75·0 (66·5, 83·6)80·1 (73·5, 86·7)74·1 (65·6, 82·7)79·7 (73·1, 86·3)Overall survival Patient deaths15 (8·0)13 (6·7)0·66116 (8·0)14 (6·9)0·701 Patients censored173 (92·0)181 (93·3)183 (92·0)189 (93·1) 1-year overall survival rate91·8 (87·8, 95·8)92·4 (88·3, 96·6)91·6 (87·6, 95·5)92·1 (88·0, 96·3)Disease-free survival Patients experiencing events27 (14·4)24 (12·4)0·46228 (14·1)25 (12·3)0·477 Patients censored161 (85·6)170 (87·6)171 (85·9)178 (87·7) 1-year disease-free survival rate77·4 (68·9, 85·9)83·0 (76·7, 89·3)76·9 (68·4, 85·4)82·6 (76·2, 88·9)Data are n (%) or %, (95% CI). Percentage values may not total 100% because of rounding

The safety analysis set (Table [2](#Tab2){ref-type="table"}) comprised 406 patients who received at least one treatment. 199/200 in H-CHOP group and 204/206 in R-CHOP group (H-CHOP 99.5%, R-CHOP 99.0%, *p* = 1.000) experienced at least one treatment-emergent adverse event; 68/200 in H-CHOP and 67/206 in R-CHOP (H-CHOP 34.0%, R-CHOP 32.5%, *p* = 0.752) experienced at least one serious adverse event; 14/200 in H-CHOP and 9/206 in R-CHOP (H-CHOP 7.0%, R-CHOP 4.4%, *p* = 0.252) discontinued treatment because of adverse events (AEs). The most common AEs were hematological events such as decreased white blood cell count (H-CHOP 85.5%; R-CHOP 85.9%), decreased neutrophil count (H-CHOP 79.0%; R-CHOP 81.6%), and anemia (H-CHOP 38.5%; R-CHOP 35.0%). Table 2Safety profiles in the safety analysis datasetH-CHOP (***n*** = 200)R-CHOP (***n*** = 206)Patients with ≥1 TEAE199 (99·5)204 (99·0)Patients with ≥1 SAE68 (34·0)67 (32·5)Patients with ≥1 AE leading to treatment discontinuation14 (7)9 (4·4)Patients deaths due to AE5 (2·5)3 (1·5)Adverse events with an incidence ≥10% Hematological  Decreased white blood cell count171 (85·5)177 (85·9)  Decreased neutrophil count158 (79·0)168 (81·6)  Anemia77 (38·5)72 (35·0)  Decreased platelet count34 (17·0)19 (9·2)  Decreased lymphocyte count24 (12·0)34 (16·5)  Decreased hemoglobin concentration23 (11·5)20 (9·7) Non-hematological  Nausea46 (23·0)49 (23·8)  Increased alanine aminotransferase49 (24·5)38 (18·4)  Fever47 (23·5)34 (16·5)  Decreased appetite32 (16·0)42 (20·4)  Increased lactate dehydrogenase30 (15·0)40 (19·4)  Debilitation38 (19·0)31 (15·0)  Alopecia35 (17·5)34 (16·5)  Increased aspartate aminotransferase34 (17·0)30 (14·6)  Cough31 (15·5)26 (12·6)  Vomiting22 (11·0)30 (14·6)  Upper respiratory tract infection19 (9·5)29 (14·1)  Hypokalemia28 (14·0)17 (8·3)  Constipation27 (13·5)25 (12·1)  Non-infectious pneumonia19 (9·5)24 (11·7)  Pulmonary infection19 (9·5)24 (11·7)  Diarrhea16 (8·0)22 (10·7)  Chills20 (10·0)14 (6·8) Adverse events by CTCAE Grade  Grade 18 (4·0)6 (2·9)  Grade 235 (17·5)35 (17·0)  Grade 354 (27·0)75 (36·4)  Grade 498 (49·0)85 (41·3)  Grade 54 (2·0)3 (1·5) Grade 4 adverse events with an incidence ≥2·5%  Decreased neutrophil count85 (42·5)75 (36·4)  Decreased white blood cell count44 (22·0)42 (20·4)  Febrile neutropenia5 (2·5)6 (2·9)  Bone marrow failure5 (2·5)5 (2·4)Data are n (%). Percentage values may not total 100% because of rounding

Among the patients observed with infusion-related reactions (IRRs), 61/200 in H-CHOP group and 61/206 in R-CHOP group (H-CHOP 30.5%; R-CHOP 29.6%), the most common reactions were those affecting skin and subcutaneous tissues. Most IRRs were grade 1 or 2, and no grade 4 or 5 IRRs were reported. Increases in hepatitis B virus (HBV) DNA titer were observed in five patients in H-CHOP group and eight patients in R-CHOP group, and nine of whom were receiving antiviral therapy for chronic HBV; however, no patients developed signs or symptoms of fulminant hepatitis.

Anti-drug antibodies (ADAs) were detected in one patient (\< 1%) in each treatment group at baseline and immediately before administration of the second treatment cycle. After 6 months of follow-up, ADAs were detected in one patient in H-CHOP group and two patients in R-CHOP group (H-CHOP 1.0%, R-CHOP 1.7%, *p* = 1.000), and after 8 months of follow-up in seven patients in H-CHOP group and six patients in R-CHOP group (H-CHOP 7.1%, R-CHOP 5.5%, *p* = 0.629). During the entire study, only one patient in R-CHOP group had both ADAs and neutralizing antibodies.

In conclusion, this study demonstrated therapeutic equivalence between HLX01 and reference rituximab. The analysis of the primary and secondary efficacy endpoints did not reveal any statistically significant differences between two treatment groups. The safety and immunogenicity profiles of HLX01 were comparable with reference rituximab with no clinically meaningful differences observed between two treatment groups.

R-CHOP

:   Rituximab plus cyclophosphamide, hydroxydaunorubicin, oncovin (vincristine), and prednisone
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:   HLX01 plus cyclophosphamide, hydroxydaunorubicin, oncovin (vincristine), and prednisone

ORR

:   Best overall response rate
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:   Per-protocol set
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:   Infusion-related reaction
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:   Hepatitis B virus
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